MNOV: Plans for Phase 2 Study of MN-001 (tipelukast) in NAFLD Patients with Type 2 Diabetes and Hypertriglyceridemia…
By David Bautz, PhD
NASDAQ:MNOV
READ THE FULL MNOV RESEARCH REPORT
MediciNova Shares Quiet But See Large Volume Spike Following Circulation Of Zack’s Small Cap Research Note Showing $27 Valuation Target
https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_05252022_MNOV_Bautz.pdf
MNOV: Genzyme Patent Litigation Could Lead to Significant Payout…
By David Bautz, PhD
NASDAQ:MNOV
READ THE FULL MNOV RESEARCH REPORT
MediciNova’s Alcohol Use Disorder Candidate Reduces Alcohol Craving, Odds Of Heavy Drinking
MediciNova Inc (NASDAQ: MNOV) announced that
MediciNova Receives Notice Of Allowance For New Patent Covering MN-001 And MN-002 For The Treatment Of Advanced NASH In Korea
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of
MNOV: Ibudilast Identified as Promising Development Candidate in Alcohol Use Disorder and Degenerative Cervical Myelopathy…
By David Bautz, PhD
NASDAQ:MNOV
READ THE FULL MNOV RESEARCH REPORT
MediciNova Announces MN-166 Identified As Potential Beneficial Pharmacotherapy For Treatment Of Degenerative Cervical Myelopathy In Global Spine Journal
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MN-166 (ibudilast) was discussed
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning trading, 152 companies set new 52-week lows.
MediciNova Receives Notice Of Allowance For New Patent Covering MN-166 For The Treatment Of ALS
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of